CN113318142A - Formula containing olive extract and preparation method and application thereof - Google Patents
Formula containing olive extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN113318142A CN113318142A CN202110667320.2A CN202110667320A CN113318142A CN 113318142 A CN113318142 A CN 113318142A CN 202110667320 A CN202110667320 A CN 202110667320A CN 113318142 A CN113318142 A CN 113318142A
- Authority
- CN
- China
- Prior art keywords
- olive extract
- parts
- capsule
- olive
- extract containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a formula containing olive extract, a preparation method and application thereof, wherein the formula is prepared from the following raw materials in parts by weight: 45-48 parts of olive extract containing 20% oleuropein; 24-25 parts of olive extract containing 30% maslinic acid; 12-13 parts of olive extract containing 20% hydroxytyrosol; 12-13 parts of olive extract containing 70% oleanolic acid; 1 part of lemon fruit powder. According to the invention, various olive extracts are prepared into a formula, so that all components of the olive extract can be fully exerted to achieve comprehensive utilization, and the four components can effectively treat and prevent various diseases and improve the immunity of the organism; the olive extract is a natural raw material, has small side effect on treating diseases, is safe and non-toxic, and is convenient to use. In addition, the addition of lemon fruit powder can improve the bitter taste of olive extract.
Description
Technical Field
The invention belongs to the technical field of application of olive extracts, and particularly relates to a formula containing olive extracts, and a preparation method and application thereof.
Background
With the improvement of living standard, the dietary structure changes. People suffering from hypertension, hyperglycemia, hyperlipidemia and hyperuricemia are more and more, and people suffering from the diseases tend to be gradually younger, so that the health problem is not ignored for the whole people. Hyperuricemia (HUA) is a metabolic disease mainly manifested by elevated blood uric acid levels, about 1.2 hundred million patients exist in China, and long-term hyperuricemia can cause urate to deposit on bone joints and kidneys to cause gout, kidney damage and the like. For diseases such as hyperuricemia and the like, pharmaceutical therapy is mostly adopted at present, and adverse effects are brought to the bodies of patients while a plurality of pharmaceutical therapies are carried out, so that a replaceable natural raw material with higher safety coefficient is urgently needed to be found. The olive extract has the effects of resisting oxidation, reducing blood sugar, reducing blood fat, reducing uric acid and the like while meeting high safety, can be used for preventing and treating related diseases, has a remarkable treatment effect, and has a good application prospect.
Disclosure of Invention
The fructus Canarii albi extract mainly contains hydroxytyrosol, oleuropein, maslinic acid, oleanolic acid, etc. Wherein the hydroxytyrosol has effects of resisting oxidation, reducing uric acid, resisting cancer, diminishing inflammation, preventing cardiovascular diseases, and protecting retina and bone; oleuropein has effects of protecting cardiovascular and cerebrovascular health, enhancing immunity, resisting oxidation, resisting broad-spectrum bacteria, and protecting skin cells from ultraviolet rays; maslinic acid has effects of protecting cardiovascular and cerebrovascular health, controlling blood sugar, resisting inflammation, resisting cancer, resisting oxidation, etc.; oleanolic acid has antioxidant, antiinflammatory, liver protecting, hepatotoxin removing, blood glucose and blood lipid reducing, platelet aggregation inhibiting, lymphocyte proliferation promoting, heart strengthening, and diuretic effects.
Based on the pharmacological effects of the olive extract, the applicant finds that the olive extract hydroxytyrosol is a particularly safe uric acid reducing component, and the action mechanism of the hydroxytyrosol for reducing urea is mainly as follows:
(1) the hydroxytyrosol molecule can combine with Xanthine Oxidase (XOD) which promotes the formation of uric acid and influence the structure of enzyme, so as to inhibit the enzyme, reduce the enzyme activity and further reduce the formation of uric acid which causes hyperuricemia.
(2) Hydroxytyrosol can modify the transcription of renal uric acid transporter genes, so that the mRNA of uric acid reabsorption transporter genes is reduced, the mRNA of secretory transporter genes is increased to be normal, and the excretion of uric acid is promoted.
Therefore, the invention uses the formula of the olive extract with reasonable proportion, can prevent/treat diseases such as hyperglycemia, hyperlipidemia, hyperuricemia and the like, thereby solving the problems of more adverse reactions and poor treatment and prevention effects of the existing treatment medicines.
Specifically, the invention is realized by the following technical scheme:
the invention provides a formula containing olive extract, which is prepared from the following raw materials in parts by weight:
45-48 parts of olive extract containing 20% oleuropein;
24-25 parts of olive extract containing 30% maslinic acid;
12-13 parts of olive extract containing 20% hydroxytyrosol;
12-13 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
As a further illustration of the present invention, the formulation can be made into one of a tablet, capsule, pill, granule or powder.
The second aspect of the present invention provides a preparation method of the above capsule, comprising the following steps:
precisely weighing the raw materials in proportion, uniformly mixing, and crushing into fine powder;
adding appropriate amount of edible ethanol, and granulating;
then putting the granules into a vacuum drier for drying;
sterilizing the dried granules to obtain filling materials of the capsule, and filling the granules into a hollow capsule shell to obtain the capsule.
As a further illustration of the invention, the raw materials crushed into fine powder need to pass through a sieve of 80-100 meshes; adding appropriate amount of edible ethanol, and sieving with 20-40 mesh sieve.
As a further illustration of the present invention, the drying conditions are: the vacuum degree is controlled to be 0.03-0.06 Mpa, the temperature is controlled to be 20-30 ℃, and the moisture of the dried particles is controlled to be less than or equal to 5 percent.
As a further explanation of the present invention, the sterilization mode is high-temperature sterilization.
As a further illustration of the invention, the hollow capsule shell is a plant capsule shell.
As a further illustration of the invention, the obtained capsules are weighed according to the mass standard, and the mass is controlled within the range of 370mg-400 mg.
In a third aspect, the invention provides the use of the above formulation in the preparation of a medicament for the prevention/treatment of hyperglycemia, hyperlipidemia and hyperuricemia.
Compared with the prior art, the invention has the following beneficial technical effects:
the olive extracts are prepared into a formula, so that all components of the olive extracts can be fully exerted to achieve comprehensive utilization, and the four components can effectively treat and prevent various diseases and improve the immunity of the organism; the olive extract is a natural raw material, has small side effect on treating diseases, is safe and non-toxic, and is convenient to use. In addition, the addition of lemon fruit powder can improve the bitter taste of olive extract.
Detailed Description
In order that the above objects, features and advantages of the present invention may be more clearly understood, the present invention will be described in detail below with reference to specific embodiments. It should be noted that the embodiments of the present invention and features of the embodiments may be combined with each other without conflict.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
Example 1:
a formulation containing olive extract, comprising different extracts of olive and a capsule shell:
the formula is prepared from the following raw materials in parts by weight:
45 parts of olive extract containing 20% oleuropein;
24 parts of olive extract containing 30% maslinic acid;
13 parts of olive extract containing 20% hydroxytyrosol;
13 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
The capsule shell is a plant capsule shell.
The preparation method of the formula containing the olive extract comprises the following steps:
step 1: precisely weighing the raw materials in the formula according to the proportion, uniformly mixing, crushing into fine powder, sieving with a 80-mesh sieve, adding a proper amount of edible ethanol, preparing into granules, sieving with a 20-mesh sieve,
step 2: drying the obtained granules in a vacuum drier under the conditions of vacuum degree of 0.03Mpa, temperature of 20 deg.C and granule moisture content of less than or equal to 5%,
and step 3: adopting a high-temperature sterilization mode to obtain a filling material of the capsule, and filling the sterilized particles into a hollow capsule shell; after the capsule is prepared, weighing according to the quality standard, and controlling the quality within the range of 370mg-400 mg.
Example 2:
a formulation containing olive extract, comprising different extracts of olive and a capsule shell:
the formula is prepared from the following raw materials in parts by weight:
48 parts of olive extract containing 20% oleuropein;
25 parts of olive extract containing 30% maslinic acid;
12 parts of olive extract containing 20% hydroxytyrosol;
12 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
The capsule shell is a plant capsule shell.
The preparation method of the formula containing the olive extract comprises the following steps:
step 1: precisely weighing the raw materials in the formula according to the proportion, uniformly mixing, crushing into fine powder, sieving with a 100-mesh sieve, adding a proper amount of edible ethanol, preparing into granules, sieving with a 40-mesh sieve,
step 2: drying the obtained granules in a vacuum drier under the conditions of vacuum degree of 0.06Mpa, temperature of 30 deg.C and granule moisture content of less than or equal to 5%,
and step 3: adopting a high-temperature sterilization mode to obtain a filling material of the capsule, and filling the sterilized particles into a hollow capsule shell; after the capsule is prepared, weighing according to the quality standard, and controlling the quality within the range of 370mg-400 mg.
Example 3:
a formulation containing olive extract, comprising different extracts of olive and a capsule shell:
the formula is prepared from the following raw materials in parts by weight:
46 parts of olive extract containing 20% oleuropein;
24 parts of olive extract containing 30% maslinic acid;
13 parts of olive extract containing 20% hydroxytyrosol;
12 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
The capsule shell is a plant capsule shell.
The preparation method of the formula containing the olive extract comprises the following steps:
step 1: precisely weighing the raw materials in the formula according to the proportion, uniformly mixing, crushing into fine powder, sieving by a 90-mesh sieve, adding a proper amount of edible ethanol, preparing into granules, sieving by a 30-mesh sieve,
step 2: drying the obtained granules in a vacuum drier under the conditions of vacuum degree of 0.04Mpa, temperature of 25 deg.C and granule moisture content of less than or equal to 5%,
and step 3: adopting a high-temperature sterilization mode to obtain a filling material of the capsule, and filling the sterilized particles into a hollow capsule shell; after the capsule is prepared, weighing according to the quality standard, and controlling the quality within the range of 370mg-400 mg.
Example 4:
a formulation containing olive extract, comprising different extracts of olive and a capsule shell:
the formula is prepared from the following raw materials in parts by weight:
47 parts of olive extract containing 20% oleuropein;
25 parts of olive extract containing 30% maslinic acid;
12 parts of olive extract containing 20% hydroxytyrosol;
13 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
The capsule shell is a plant capsule shell.
The preparation method of the formula containing the olive extract comprises the following steps:
step 1: precisely weighing the raw materials in the formula according to the proportion, uniformly mixing, crushing into fine powder, sieving by a 90-mesh sieve, adding a proper amount of edible ethanol, preparing into granules, sieving by a 30-mesh sieve,
step 2: drying the obtained granules in a vacuum drier under the conditions of vacuum degree of 0.05Mpa, temperature of 25 deg.C and granule moisture content of less than or equal to 5%,
and step 3: adopting a high-temperature sterilization mode to obtain a filling material of the capsule, and filling the sterilized particles into a hollow capsule shell; after the capsule is prepared, weighing according to the quality standard, and controlling the quality within the range of 370mg-400 mg.
The clinical trial effect is as follows:
anti-blood sugar curative effect: 40-50 patients with hyperglycemia take the capsules prepared in example 4, and after eating the capsules for 2-3 months (two capsules per day), the blood sugar level reduction rate reaches 20% -30%.
Blood fat reducing effect: 40-50 patients with hyperlipidemia are selected to take the capsules prepared in example 4, and after eating the capsules for 6 months (two capsules per day), low-density lipoprotein is obviously reduced, and triglyceride and cholesterol are both reduced by 10% -20%.
The efficacy of reducing uric acid: 40-50 patients with hyperuricemia who take the capsules prepared in example 4 are selected, and after eating the capsules for 6-12 months (two capsules per day), the uric acid level is reduced to be lower than the maximum limit value.
Finally, it should be noted that the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. The formula containing the olive extract is characterized by being prepared from the following raw materials in parts by weight:
45-48 parts of olive extract containing 20% oleuropein;
24-25 parts of olive extract containing 30% maslinic acid;
12-13 parts of olive extract containing 20% hydroxytyrosol;
12-13 parts of olive extract containing 70% oleanolic acid;
1 part of lemon fruit powder.
2. The olive extract-containing formulation according to claim 1, wherein the formulation is in the form of one of a tablet, a capsule, a pill, a granule or a powder.
3. A method for preparing the capsule of claim 2, comprising the steps of:
precisely weighing the raw materials in the claim 1 in proportion, uniformly mixing, and crushing into fine powder;
adding appropriate amount of edible ethanol, and granulating;
then putting the granules into a vacuum drier for drying;
sterilizing the dried granules to obtain filling materials of the capsule, and filling the granules into a hollow capsule shell to obtain the capsule.
4. The method for preparing a capsule according to claim 3, wherein the raw material pulverized into fine powder is sieved with a sieve of 80-100 meshes; adding appropriate amount of edible ethanol, and sieving with 20-40 mesh sieve.
5. The process for the preparation of capsules according to claim 3, wherein the drying conditions are: the vacuum degree is controlled to be 0.03-0.06 Mpa, the temperature is controlled to be 20-30 ℃, and the moisture of the dried particles is controlled to be less than or equal to 5 percent.
6. The method for producing a capsule according to claim 3, wherein the sterilization means is high-temperature sterilization.
7. The method for preparing a capsule according to claim 3, wherein the hollow capsule shell is a plant capsule shell.
8. The process for the preparation of capsules according to claim 3, wherein the capsules obtained are weighed according to a mass standard, the mass being controlled within the range of 370mg to 400 mg.
9. Use of the formulation of claim 1 for the preparation of a medicament for the prevention/treatment of hyperglycemia, hyperlipidemia and hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110667320.2A CN113318142A (en) | 2021-06-16 | 2021-06-16 | Formula containing olive extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110667320.2A CN113318142A (en) | 2021-06-16 | 2021-06-16 | Formula containing olive extract and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113318142A true CN113318142A (en) | 2021-08-31 |
Family
ID=77423228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110667320.2A Pending CN113318142A (en) | 2021-06-16 | 2021-06-16 | Formula containing olive extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113318142A (en) |
-
2021
- 2021-06-16 CN CN202110667320.2A patent/CN113318142A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| *****: ""华茂产品---橄榄叶提取物化学成分分析"", 《HTTPS://MAX.BOOK118.COM/HTML/2017/1225/145893339.SHTM》 * |
| 岳慧娟等: ""橄榄油中羟基酪醇的研究进展"", 《食品工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3626249A2 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
| JPH0745521B2 (en) | Antihypertensive agent having antihypertensive effect | |
| CN104366636A (en) | Gynura procumbens compound preparation as well as preparation method and application thereof | |
| KR102121153B1 (en) | Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof | |
| CN103637197A (en) | Propolis soft capsule and preparation method thereof | |
| EP3533446A1 (en) | Composition for protecting eyesight and preparation method therefor | |
| CN107981351B (en) | Dietary microcapsule particle for regulating body fat rate and preparation method thereof | |
| EP3616697B1 (en) | Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition comprising berberine and oryzanol | |
| CN113318142A (en) | Formula containing olive extract and preparation method and application thereof | |
| CN110693029A (en) | Mulberry leaf and bitter gourd functional food capable of reducing blood sugar | |
| CN110227095A (en) | A kind of anti-trioxypurine composition and preparation method thereof | |
| CN107136269B (en) | Cyclocarya paliurus and bitter gourd blood sugar reducing tea and preparation method thereof | |
| CN114848699B (en) | Composition with uric acid reducing effect and preparation method and application thereof | |
| CN109645295A (en) | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health | |
| CN108159101A (en) | A kind of pharmaceutical composition containing Carlina acaulis extract and preparation method thereof | |
| KR101227922B1 (en) | Papaya puree and the use of the same | |
| CN101433597A (en) | Chinese medicinal composition with function for reducing blood sugar and preparation method thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN106901382A (en) | A kind of health care preparation for treating pregnant woman's flu | |
| CN113384612A (en) | Anti-gout composition and preparation method and application thereof | |
| CN116210900B (en) | Plant polyphenol sustained-release composition for regulating xanthine oxidase activity and accurate nutrient and preparation method thereof | |
| KR20150018167A (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
| CN116942742B (en) | Uric acid reducing traditional Chinese medicine composition and preparation method thereof | |
| CN114159480B (en) | Composition with weight-losing effect and preparation method and application thereof | |
| CN113632903B (en) | Turbid-discharging and beautifying composition and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |